NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
23.55
+0.13 (0.56%)
At close: Jan 17, 2025, 4:00 PM
25.00
+1.45 (6.16%)
Pre-market: Jan 21, 2025, 5:07 AM EST
NAMS Employees
NewAmsterdam Pharma Company had 29 employees as of December 31, 2023. The number of employees increased by 12 or 70.59% compared to the previous year.
Employees
29
Change (1Y)
12
Growth (1Y)
70.59%
Revenue / Employee
$1,158,414
Profits / Employee
-$6,859,172
Market Cap
2.52B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 29 | 12 | 70.59% |
| Dec 31, 2022 | 17 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
NAMS News
- 11 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 weeks ago - NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts - Seeking Alpha
- 5 weeks ago - Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
- 5 weeks ago - NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - Benzinga
- 6 weeks ago - NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia - GlobeNewsWire